Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in India / NCT07587138
Recruiting Not applicable

Clinical Evaluation of a Novel Trifocal IOL

NCT07587138 · tracked via the Priya Life Science India tracker
Sponsor
Alcon Research
Phase
Not applicable
Started
2026-10-09
Last updated
2026-10-21

Condition(s) studied

AphakiaCataract

Investigational drug(s) / intervention(s)

LPYWT0PXYWT0Cataract Surgery

LPYWT0: Investigational blue light filtering trifocal IOL implanted in the capsular bag of the eye during cataract surgery intended to remain in the eye for the lifetime of the subject.

PXYWT0: Commercially available blue light filtering trifocal IOL implanted in the capsular bag of the eye during cataract surgery intended to remain in the eye for the lifetime of the subject.

Cataract Surgery: Removal of the cataractous lens by phacoemulsification followed by implantation of the IOL

Study summary

The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to "0.0" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery. * Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D). * In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20/32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes. * Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk. * People who want to have one eye set for distance vision and the other for near vision. * The doctor expects significant blurry vision (astigmatism) after the procedure. * Other protocol-specified exclusion criteria may apply.

Primary outcome measure(s)

  • Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) — Month 6 postoperative
    Visual Acuity will be assessed using letter charts under well-lit (photopic) conditions with correction in place at a distance of 4 meters from the subject. BCDVA will be recorded in logarithm minimum angle of resolution (logMAR) where 0.0 logMAR is equivalent to 20/20 Snellen, or normal distance eyesight, and negative logMAR values represent better-than-normal distance eyesight.

Trial sites (5)

FacilityCityRegionStatus
Personaleyes Sydney New South Wales Not Yet Recruiting
Dr. Agarwal's Eye Hospital Limited Chennai Tamil Nadu Not Yet Recruiting
Narayana Nethralaya Bangalore India Not Yet Recruiting
Peregrine Eye Laser and Institute Makati City Manila Not Yet Recruiting
Asian Eye Institute Makati City Philippines Recruiting

More Alcon Research trials in India

Capella Scientia Development Study Recruiting

Other trials for the same condition

Capella Scientia Development Study Recruiting
Strengthening Community- to- Hospital Eye Care Pathways From Boko Eye Care Center in Rural Assam Starting soon
A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07587138 on ClinicalTrials.gov ↗ ← All trials in India